COVID Vaccines/Therapeutics – Developer/Manufacturer Announcements
[Selected press releases/announcements from organizations from WHO EUL/PQ listing above and other organizations]
AstraZeneca
Press Releases – No new digest announcements identified
Bharat Biotech
Press Releases – No new digest announcements identified
BioCubaFarma – Cuba
Últimas Noticias – Website not leading at inquiry
Biontech
Press Releases
Pfizer and BioNTech Receive Positive CHMP Opinion for COVID-19 Vaccine Booster in Adolescents 12 through 17 Years of Age in the European Union
24 February 202
CanSinoBIO
News – [Website not responding at inquiry]
Clover Biopharmaceuticals – China
News – No new digest announcements identified
Curevac [Bayer Ag – Germany]
News – Website not responding at inquiry
Gamaleya National Center
Latest News and Events – See Russia below
IMBCAMS, China
Home – Website not responding at inquiry
Janssen/JNJ
Press Releases – No new digest announcements identified
Moderna
Press Releases
February 24, 2022
EMA Committee for Medicinal Products for Human Use (CHMP) Adopts Positive Opinion Recommending Authorization for The Use of The Moderna Covid-19 Vaccine in Children (6-11 Years) In the European Union
February 23, 2022
Moderna and Thermo Fisher Scientific Announce Long-Term Strategic Collaboration
Agreement to leverage dedicated commercial fill-finish manufacturing capacity in the US for mRNA vaccines and therapies
Novavax
Press Releases
Novavax Announces Shipments of its COVID-19 Vaccine to European Union Member States
Feb 23, 2022
Pfizer
Recent Press Releases
02.24.2022
Pfizer and BioNTech Receive Positive CHMP Opinion for COVID-19 Vaccine Booster in Adolescents 12 through 17 Years of Age in the European Union
Sanofi Pasteur
Press Releases
February 23 2022
Press releases
Sanofi and GSK to seek regulatory authorization for COVID-19 vaccine
* Final analysis of the global VAT02 booster trial confirms universal ability to boost neutralizing antibodies 18- to 30-fold across vaccine platforms (mRNA, adenovirus)
* In the VAT08 Phase 3 primary series trial, two doses of the Sanofi-GSK vaccine in seronegative populations demonstrated:
* 100% efficacy against severe COVID-19 disease and hospitalizations
* 75% efficacy against moderate or severe COVID-19 disease
* 57.9% efficacy against any symptomatic COVID-19 disease, in line with expected vaccine effectiveness in today’s environment dominated by variants of concern
* Favorable safety profile following both primary series and booster vaccinations
Serum Institute of India
NEWS & ANNOUNCEMENTS – No new digest announcements identified
Shifa Pharmed [Iran]
http://shafapharmed.com/
No news page identified.
Sinopharm/WIBPBIBP
News – No new digest announcements identified
Sinovac
Press Releases – No new digest announcements identified
Vector State Research Centre of Viralogy and Biotechnology
Home – No new digest announcements identified
Zhifei Longcom, China
[Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.]
[No website identified]
::::::
GSK
Press releases for media
Medicago and GSK announce the approval by Health Canada of COVIFENZ®, an adjuvanted plant-based COVID-19 vaccine
24 February 2022 Medicago, a biopharmaceutical company headquartered in Quebec City, and GlaxoSmithKline (GSK) today announced that Health Canada has granted approval for COVIFENZ®, COVID-19 vaccine, (plant-based virus-like particles [VLP], recombinant, adjuvanted). This vaccine is indicated for active immunization to prevent coronavirus disease 2019 (COVID19) caused by severe acute respiratory syndrome coronavirus 2 (SARSCoV2) in individuals 18 to 64 years of age…
23 February 2022 Sanofi and GSK to seek regulatory authorization for COVID-19 vaccine
Merck
News releases – No new digest announcements identified
Novartis
News – No new digest announcements identified
SK Biosciences
Press releases – No new digest announcements identified
Valneva
Press Releases
February 25, 2022
Valneva Receives Initial CHMP Assessment of its Inactivated, Adjuvanted COVID-19 Vaccine Candidate VLA2001
February 21, 2022
Valneva Awarded Up to £20 Million by Scottish Enterprise to Advance Vaccine Development
vaccines and global health :: ethics and policy 